Gallstone disease secondary prevention

Jump to navigation Jump to search

Gallstone disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gallstone disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Lithotripsy
Surgical management

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gallstone disease secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gallstone disease secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gallstone disease secondary prevention

CDC on Gallstone disease secondary prevention

Gallstone disease secondary prevention in the news

Blogs on Gallstone disease secondary prevention

Directions to Hospitals Treating Gallstone disease

Risk calculators and risk factors for Gallstone disease secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

Effective measures for the secondary prevention of symptoms developing in an asymptomatic case or for preventing complications with symptomatic gallstone disease includes bile acid therapy. However, medical therapy of asymptomatic stones is not currently indicated.

Secondary Prevention

  • These preventive measures aim to prevent the development of symptoms in those patients who are discovered incidentally to have gallstones and to prevent complications in a symptomatic patient.[1]
  • Effective measures for secondary prevention of gallstone disease include:

References

  1. Rubin RA, Kowalski TE, Khandelwal M, Malet PF (1994). "Ursodiol for hepatobiliary disorders". Ann. Intern. Med. 121 (3): 207–18. PMID 8017748.

Template:WH Template:WS